- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01129076
Perceptions of Thalassemia Major in Singapore: An Exploratory Study of Stigma
14 décembre 2019 mis à jour par: National Human Genome Research Institute (NHGRI)
Background:
- Thalassemia major (TM) is a chronic disorder that affects a person s ability to produce hemoglobin, resulting in anemia. Hemoglobin is a component of red blood cells that carries oxygen and nutrients to cells in the body. As a result, individuals require life-long blood transfusions and extensive medical management. Studies have shown that because of its demanding nature, TM might negatively affect an individual s quality of life, sense of self, and social integration, but little is known about affected individuals overall experiences with and perceptions of TM.
- TM is caused by a genetic change in the thalassemia gene. The disease is passed to children by parents who carry one copy of the altered thalassemia gene. The parents are called carriers of the condition and have a 25 percent chance of having a child with TM. It is possible to screen for carriers of TM and use this information for pregnancy planning and management.
- TM is common among people from South and South East Asia and is an important public health concern in Singapore. More research is needed to explore the lives of people with TM, and the societal perceptions that exist in Singapore about TM.
Objectives:
- To describe the familial, social, and professional experiences of individuals with TM.
- To investigate the social messages being given out about TM in Singapore and the sources of those messages.
- To explore the impact of these experiences, perceptions, and social messages on individuals who have TM.
- To explore how the experiences and perceptions of individuals who have TM affect their life, sense of self, social integration, and compliance with medical treatment.
Eligibility:
- Residents of Singapore who are 14 years of age or older, can speak English, and currently have TM.
- Parents of individuals with TM who are 14 years of age or older. Parents must be 21 years of age or older, be able to speak English, and have had caregiving responsibilities for their child at some point.
Design:
- All participants will have a one-time semi-structured interview, followed by a questionnaire to obtain demographic information.
- Interviews will be conducted in Singapore and are expected to last for 30 to 90 minutes.
- Individuals with TM will be asked about their own perceptions of TM; familial, social, and professional experiences involving TM; and their perceptions of others views and of social messages related to TM.
- Parents of individuals with TM will be asked about their experiences in caring for a child with TM, talking to their child about TM, telling people about their child s TM, and interacting with health care providers.
Aperçu de l'étude
Statut
Complété
Les conditions
Description détaillée
Thalassemia major (TM) is a chronic, inherited hematological disorder that can require life-long medical care.
As a result of the chronic and demanding nature of the condition, studies have shown that TM might negatively affect an individual s quality of life, sense of self, social integration, and compliance with medical treatment.
Yet, little is known about affected individuals overall experiences with and perceptions of TM.
In this study, the concept of stigma will be used to explore and understand these experiences and perceptions in the population of individuals with TM in Singapore.
This study will involve qualitative interviews with TM patients and parents of TM patients.
Interviews will focus on individuals family, social and professional experiences with TM; the social messages that exist in Singapore about TM and their sources; individuals perceptions of how others view TM; individuals own perceptions of TM; and the impact of these various experiences, messages and perceptions on the individual with TM.
Interviews will be conducted with approximately 20-30 individuals with TM, and 10-20 parents of individuals with TM.
Interviews will be transcribed and subjected to thematic analysis to identify common themes.
The results of this study will further our understanding of the psychosocial burden of TM and the potential role of stigma in this population, which may ultimately inform the care for individuals with TM.
The study s setting will also provide insights into the impact of the Singaporean sociocultural context on the psychosocial elements of living with a genetic condition, which might eventually help to inform the development of appropriate psychosocial support services and genetic counseling services in the region.
Type d'étude
Observationnel
Inscription (Réel)
30
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Singapore, Singapour
- KK Women's & Children's Hospital
-
Singapore, Singapour, 169608
- Singapore General Hospital Outram Rd.
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
14 ans et plus (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
- INCLUSION CRITERIA:
- Individuals who currently have TM and receive at least 8 blood transfusions in a year
- Residents of Singapore
- Must speak English
- Parents of individuals with TM will be eligible for participation if they are age 21 years or older
- Parents must be residents of Singapore
- Parents must speak English
- For a parent to participate in the study, it will not be required that his or her child also participate in the study or vice versa.
EXCLUSION CRITERIA:
- Children under age 14 years
- Non-English speaking individuals
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Major B, O'Brien LT. The social psychology of stigma. Annu Rev Psychol. 2005;56:393-421. doi: 10.1146/annurev.psych.56.091103.070137.
- Ismail A, Campbell MJ, Ibrahim HM, Jones GL. Health Related Quality of Life in Malaysian children with thalassaemia. Health Qual Life Outcomes. 2006 Jul 2;4:39. doi: 10.1186/1477-7525-4-39.
- Hoedemaekers R, ten Have H. Geneticization: the Cyprus paradigm. J Med Philos. 1998 Jun;23(3):274-87. doi: 10.1076/jmep.23.3.274.2585.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
23 avril 2010
Achèvement de l'étude
7 janvier 2016
Dates d'inscription aux études
Première soumission
21 mai 2010
Première soumission répondant aux critères de contrôle qualité
21 mai 2010
Première publication (Estimation)
24 mai 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
17 décembre 2019
Dernière mise à jour soumise répondant aux critères de contrôle qualité
14 décembre 2019
Dernière vérification
7 janvier 2016
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 999910104
- 10-HG-N104
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .